「d2」の検索結果
416件:61~65件目を表示
-

December 22, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Mochida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf -

OTC Products, etc. | Products | SENJU Pharmaceutical
Inquiries are not accepted in a language other than Japanese in principle. Please kindly understand the situation that the inquiries by telephone must use Japanese only. Translated from the Japanese p
http://www.senju.co.jp/english/products/clp.html -

Business Activities | About Senju | SENJU Pharmaceutical
Based on a sense of mission to contribute to the health of the eyes of people around the world, and a development policy that puts top priority on safety, we have always taken a pioneering path in oph
https://www.senju.co.jp/english/about/business/ -

NewMytear A | OTC Products, etc. | Products | SENJU Pharmaceutical
Category 3 OTC medicines New Mytear® A Supplies moisture. CHARACTERISTICS This is an artificial tear-type eye drop with mild sensation. It supplies the moisture of tears that is important to the eyes
http://www.senju.co.jp/english/products/myteara.html -

ピマリシン眼軟膏1%「センジュ」
貯 法:室温保存 有効期間: 3 年 2023年 7 月改訂 (第 1 版) 注) 注意─医師等の処方箋により使用すること ─ 1 ─ 3. 組成・性状 3. 1 組成 3. 2 製剤の性状 4. 効能又は効果 角膜真菌症 6. 用法及び用量 通常、1 回適量を 1 日 4 ∼ 5 回塗布する。なお、症状に より適宜回数を増減する。 9. 特定の背景を有する患者に関する注意 9. 5 妊婦 妊婦
https://www.senju.co.jp/system/files/product_other_file/2023-06/pimaricin-1_202307_C9.pdf